Loading cancer entity…
Loading cancer entity…
Clinical trials
8,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,291)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07025005 | Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)(VRd MM Fibrate) | recruiting | Phase 4 | 44 | Tanta UniversityOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06569680 | Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma | recruiting | Phase 2 | 35 | Izidore Lossos, MDOTHER | 1 | Nov 3, 2025 |
| clinicaltrials |
| NCT00368082 | Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)(TGF-beta) | active not recruiting | Phase 1 | 8 | Baylor College of MedicineOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT03229200 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | active not recruiting | Phase 4 | 297 | Pharmacyclics Switzerland GmbHINDUSTRY | 17 | Oct 30, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05363111 | Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT06796998 | Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) | recruiting | Phase 2 | 25 | Izidore Lossos, MDOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT02848274 | ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome | recruiting | — | 2,000 | Stanford UniversityOTHER | 7 | Oct 22, 2025 | clinicaltrials |
| NCT00881920 | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL(CHARKALL) | active not recruiting | Phase 1 | 54 | Baylor College of MedicineOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT05890352 | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | recruiting | Phase 2 | 227 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 20, 2025 | clinicaltrials |
| NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06544798 | Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia | enrolling by invitation | Phase 2 | 276 | MeiraGTx, LLCINDUSTRY | 2 | Oct 16, 2025 | clinicaltrials |
| NCT05371093 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma(ZUMA-22) | active not recruiting | Phase 3 | 231 | Kite, A Gilead CompanyINDUSTRY | 7 | Oct 15, 2025 | clinicaltrials |
| NCT00626496 | Family Study of Lymphoproliferative Disorders | recruiting | — | 3,000 | Mayo ClinicOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06520098 | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(Benefit VA) | recruiting | Phase 2 | 100 | VA Office of Research and DevelopmentFED | 1 | Oct 14, 2025 | clinicaltrials |
| NCT02909036 | Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | active not recruiting | Phase 1 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT03016806 | Umbilical Cord Blood Transplantation From Unrelated Donors | recruiting | — | 30 | University of RochesterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05270057 | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies(LONCA) | active not recruiting | Phase 1 | 11 | Medical College of WisconsinOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT05940272 | Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers | recruiting | N/A | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT07213882 | A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)(CITY) | not yet recruiting | Early Phase 1 | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 9, 2025 | clinicaltrials |
| NCT07202052 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202065 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202078 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202091 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT02153580 | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | active not recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07207785 | PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma(FIL_PUMA) | not yet recruiting | Phase 2 | 56 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07208981 | Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL | recruiting | Phase 2 | 169 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07209163 | Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 48 | Ruijin HospitalOTHER | 0 | Oct 6, 2025 | clinicaltrials |
| NCT05556720 | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial(BOOST-IC) | active not recruiting | Phase 3 | 960 | Monash UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06534060 | MB-105 in Patients With CD5 Positive T-cell Lymphoma | recruiting | Phase 2 | 46 | March Biosciences IncINDUSTRY | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07205523 | High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)(HALO-SCT) | recruiting | — | 1,000 | Yigeng Cao,MD,PhDOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07206264 | Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment(ADAPT-MCL) | not yet recruiting | Phase 2 | 45 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05878184 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | active not recruiting | Phase 1 | 16 | Sana BiotechnologyINDUSTRY | 2 | Oct 2, 2025 | clinicaltrials |
| NCT05932680 | Limited-duration Teclistamab | recruiting | Phase 2 | 75 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT03327597 | Iceland Screens, Treats or Prevents Multiple Myeloma(iStopMM) | active not recruiting | N/A | 80,761 | University of IcelandOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06925555 | Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS | not yet recruiting | Phase 2 | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198464 | Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma | not yet recruiting | N/A | 30 | Zhengzhou UniversityOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT07199296 | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment | recruiting | Phase 2 | 45 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03147885 | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 43 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04479267 | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma | active not recruiting | Phase 2 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06979076 | A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL | not yet recruiting | Phase 1 / Phase 2 | 12 | MingSight Pharmaceuticals, IncINDUSTRY | 0 | Sep 29, 2025 | clinicaltrials |
| NCT07195799 | Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL | recruiting | Phase 2 | 180 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04606433 | Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 47 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05192486 | A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 1 / Phase 2 | 12 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05485753 | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | active not recruiting | Phase 1 / Phase 2 | 7 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Nov 4, 2025source: clinicaltrials